Tuesday’s analyst upgrades and downgrades

Analysts turned generally constructive across several names, led by Boralex’s $3.8B takeout and higher targets for Boralex (to $37.25), Ovintiv (to US$82), Rogers (to $63), Doman (to $12.50), and others. Ovintiv beat Q1 production and cash flow estimates with 679,000 boe/d and $4.62/share cash flow, while Doman reported 17.0% gross margin and EPS of 27 cents, both ahead of forecasts. The main negatives were smaller target cuts for AGT, Brookfield Business, Fiera Capital and Cineplex, but overall analyst tone was constructive with emphasis on buybacks, debt reduction and M&A optionality.

Analysis

The clearest second-order winner is BAM, not BLX. This type of acquisition reinforces Brookfield’s repeatable playbook: take development-heavy renewables platforms that are capital constrained, then re-rate them through cheaper funding, better procurement, and monetized recycling. The more important implication is competitive pressure on standalone renewable developers across Canada/Europe: financing spreads, equipment sourcing, and offtake access should all improve for large platforms while smaller peers face a higher hurdle rate and may be forced into similar strategic processes.

For BLX, the deal is less about the takeout premium and more about removing a financing overhang. The market should start discounting a lower probability of dilutive equity issuance and execution risk in the pipeline, but that also caps upside because the valuation is now largely anchored to deal certainty rather than project optionality. The key watchpoint is regulatory and shareholder timing over the next 3–6 weeks; any slippage there likely compresses the spread more than it changes fundamental value.

OVV remains the best near-term free-cash-flow momentum story in the group. The combination of debt paydown and buybacks creates a levered equity compounding effect: each incremental dollar of commodity upside is now split between faster capital return and lower enterprise risk, which supports multiple expansion even if production is only modestly growing. The market is still underestimating how much a better Waha basis can matter over 12–24 months; that can translate into sustained revisions rather than a one-quarter beat.

The more contrarian setup is DBM and EXE, where the street is still treating current strength as cyclical rather than structural. In both cases, the operating model is improving while the macro narrative remains cautious, which creates room for estimate ratchets and multiple re-rating if volumes hold into late 2026. Conversely, RCI’s sports-media asset value story is real but likely less liquid than bulls assume; monetization events may lift NAV slowly, but they also create sequence risk if league expansion timelines slip or valuation marks get too aggressive.

Key Decisions for Investors

• Long BLX.TO into the shareholder vote / approval window (1-3 months): buy the deal spread for low-single-digit downside if the transaction stays on track; trim if approval or financing commentary deteriorates.
• Long BAM against a basket of smaller renewable developers over 6-12 months: Brookfield’s scale should widen its access-to-capital advantage; the short basket captures financing pressure on sub-scale peers.
• Stay long OVV on any pullback over the next 1-2 quarters: thesis is continued FCF surprise, faster buybacks, and basis improvement; downside is mainly a sharp gas-price retracement or a reset in capital-return pacing.
• Long DBM.TO for 6-9 months: margin resilience plus underappreciated fencing capacity expansion should support estimate upgrades; risk is housing affordability keeping volumes soft longer than expected.
• Long EXE.TO, but use staged entries over 3-6 months: structural ALC/hospital-capacity backdrop supports organic growth; risk is the market reclassifying recent volume gains as temporary if capacity normalizes faster than expected.